| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1895 | Ebi-13a | Highly potent and selective activator of isozymes CA-VA and CA-VII |
|
| DCC1896 | Ebmi-13b | Highly potent and selective activator of isozymes CA-VA and CA-VII |
|
| DCC1897 | Ebopiprant | Novel Oral and Selective Prostaglandin F 2α (PGF 2α ) Receptor Antagonist |
|
| DCC1898 | Ebov-in-c31 | Novel PP1-targeting Ebola Virus (EBOV) inhibitor with improved pharmacological properties |
|
| DCC1899 | Ebselen Oxide | Novel dose-dependent inhibitor of HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9, inhibiting Pseudomonas aeruginosa alginate synthesis |
|
| DCC1900 | Ebv Activator C60 | Novel EBV activator, well-performing EBV lytic cycle inducer |
|
| DCC1901 | Ecdsbb-in-12 | Novel potent specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme |
|
| DCC1902 | Ecdsbb-in-9 | Novel specific inhibitor of EcDsbB, targeting disulfide bond forming enzyme DsbB of Gram-negative bacteria |
|
| DCC1903 | Echinoside A | Novel marine-derived anticancer saponin, targeting topoisomerase2alpha by unique interference with its DNA binding and catalytic cycle |
|
| DCC1904 | Ecraprost | Lipo-pro-prostaglandin E1, preventing hearing disturbance and equilibrium dysfunction due to inner ear microcirculatory disorders |
|
| DCC1905 | Edoxaban Isomer | An impurity of Edoxaban, a novel inhibitor of factor Xa |
|
| DCC1906 | Eef2k-in-21i | Novel eEF2K inhibitor, inducing significant apoptosis through classical apoptotic pathways |
|
| DCC1907 | Efatutazone | Potent agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma) with potential antineoplastic activity |
|
| DCC1908 | Efonidipine | Calcium channel blocker, blocking both T-type and L-type calcium channels |
|
| DCC1909 | Efrapeptin F | Natural alpha-aminobutyric acid-rich secondary metabolite of fungi, strongly inhibiting the BBMV V-ATPase, acting as a mitochondrial complex V inhibitor, showing antitumor activity in vivo |
|
| DCC1910 | Efrotomycin | Antibiotic, inhibiting bacterial protein synthesis |
|
| DCC1911 | Egfr T790m Inhibitor 6a | Novel third-generation EGFR tyrosine kinase inhibitor, targeting EGFR T790M mutation in advanced non-small cell lung cancer |
|
| DCC1912 | Egfr-in-451 | Novel EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis |
|
| DCC1913 | Egfr-in-542 | Novel EGFR inhibitor, significantly reducing myocardial inflammation, fibrosis, apoptosis, and dysfunction, showing promises to the treatment on obesity-induced cardiac complications |
|
| DCC1914 | Egfr-in-557 | Novel EGFR inhibitor, attenuating Ang II-induced Kidney Fibrosis |
|
| DCC1915 | Egis-11150 | Potent inhibitor of adrenergic alpha1, alpha2c, 5-HT2a, 5HT7 receptors; Relatively selective blocker of adrenergic alpha2c over adrenergic alpha2a receptors. |
|
| DCC1916 | Egis-8332 | Selective, non-competitive AMPA receptor antagonist, improving motor co-ordination |
|
| DCC1917 | Egonol | Antibacterial agent |
|
| DCC1918 | Eh-201 | Arginase Inhibitor, activating EPO-mediated mitochondrial function and haemoglobin expression, stimulating melanogenesis by MAP kinase activation and tyrosinase upregulation |
|
| DCC1919 | Ehi1471 | Potent and bio-stable inhibitor of the chicken sEH (chxEH) |
|
| DCC1920 | Ehi2119 | Potent and bio-stable inhibitor of the chicken sEH (chxEH) |
|
| DCC1921 | Ehi2225 | Potent and bio-stable inhibitor of the chicken sEH (chxEH) |
|
| DCC1922 | Eht5372 | Novel Mirk kinase inhibitor, inhibiting DYRK1A-induced Tau phosphorylation at multiple AD-relevant sites, blocking the in vivo growth of pancreatic cancer cells |
|
| DCC1923 | Eidd-1619 | Novel water-soluble analog of progesterone |
|
| DCC1924 | Eidd-1723 | Novel water-soluble analog of progesterone, reducing cerebral edema and lesion size and improving functional recovery, decreasing glial fibrillary acidic protein expression immunoreactivity |
|
